ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Neurocrine's 3rd Ingrezza flop in Tourette dashes hopes for sales expansion
December 14, 2018Last year, Neurocrine’s Ingrezza failed a phase 2 trial in pediatric Tourette Syndrome patients, prompting the company to use what it learned in designing a new phase 2b. But now Ingrezza has flunked that trial, too. -
Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome
December 13, 2018Neurocrine Biosciences announced topline data from the Phase IIb T-Force GOLD study demonstrating that valbenazine did not meet the primary endpoint .....
Pharma Sources Insight January 2025
